Jupiter Neurosciences, Inc. cash flow statement JUNS

In fiscal 2025, which ended Dec 31, 2025, Jupiter Neurosciences, Inc. used $5.4 million of cash from operations, down 38.4% from the year before.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
Operating
Stock-based compensation
3
2
+31.4%
2
Operating cash flow
-7
-5
-38.4%
-4
Financing
Financing cash flow
7
5
-29.0%
8
Change in cash
Net change in cash
-0
0
-99.5%
4
Ratios
Stock-based compensation to revenue
—
11,096.15%
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
JUNS (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Jupiter, FL
SEC filer status
, Emerging growth company
SEC CIK
1679628
Former names
Jupiter Orphan Therapeutics, Inc. (until Dec 5, 2017)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.